A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF- κ B pathway.

MLA

Yoon, Sae-Bom, et al. “A Novel IRAK4/PIM1 Inhibitor Ameliorates Rheumatoid Arthritis and Lymphoid Malignancy by Blocking the TLR/MYD88-Mediated NF- κ B Pathway.” Acta Pharmaceutica Sinica. B, vol. 13, no. 3, Mar. 2023, pp. 1093–109. EBSCOhost, https://doi.org/10.1016/j.apsb.2022.12.001.

APA

Yoon, S.-B., Hong, H., Lim, H.-J., Choi, J. H., Choi, Y. P., Seo, S. W., Lee, H. W., Chae, C. H., Park, W.-K., Kim, H. Y., Jeong, D., De, T. Q., Myung, C.-S., & Cho, H. (2023). A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF- κ B pathway. Acta Pharmaceutica Sinica. B, 13(3), 1093–1109. https://doi.org/10.1016/j.apsb.2022.12.001

Chicago

Yoon, Sae-Bom, Hyowon Hong, Hee-Jong Lim, Ji Hye Choi, Yoon Pyo Choi, Seong Wook Seo, Hyuk Woo Lee, et al. 2023. “A Novel IRAK4/PIM1 Inhibitor Ameliorates Rheumatoid Arthritis and Lymphoid Malignancy by Blocking the TLR/MYD88-Mediated NF- κ B Pathway.” Acta Pharmaceutica Sinica. B 13 (3): 1093–1109. doi:10.1016/j.apsb.2022.12.001.